April 24, 2011

I am writing on behalf of MSF to express our disappointment that J&J has not yet placed any patent into the Medicines Patent Pool and that it has announced in a recent letter to the Medicines Patent Pool that it is not ready to engage in formal negotiations.

April 30, 2008

My name is Dr. Tido von Schoen-Angerer and I am speaking on behalf of Médecins Sans Frontières. Thank you for the opportunity to address this important gathering.

In 2000, I was working in one of MSF’s AIDS projects. Our response to the pandemic was one based on a simple medical decision: faced with the urgency of patients dying, the only acceptable response was to treat. This was an ethical imperative, to treat, regardless of the difficulties.

July 28, 2004

Speech by STEPHEN LEWIS, UN Special Envoy for HIV/AIDS in Africa

December 15, 2003

Testimony from MSF Submitted to the Department of Health and Human Services for the Meeting of the International Subcommittee of the Presidential Advisory Council on HIV/AIDS Townhall Meeting on the President's Emergency Plan for AIDS Relief (PEPFAR) Delivered By Rachel M. Cohen, U.S. Director, MSF Campaign for Access to Essential Medicines

February 12, 2003

cc: Mr JG Zuma; Deputy President; Fax: 012 3233114 Mr A. Erwin; Minister of Trade and Industry; Fax: 012 3227851 Treatment Action Campaign (TAC), info@tac.org.za

Mr TM Mbeki
President of the Republic of South Africa
Fax: 012 3238246

Dear Sir,

July 06, 2002

A Satatement Delivered by Fred Minandi in Barcelona, Spain, at a satellite meeting co-sponsored by MSF and Health Gap of the XIV International AIDS Conference

July 15, 2001

A Congressional Briefing delivered in Washington, D.C. by Rachel Cohen, Advocacy Liaison for MSF's Access to Essential Medicines Campaign

June 20, 2001

An MSF-sponsored panel discussion held at the Graduate Center, CUNY

April 24, 2000

Delivered by Joelle Tanguy, U.S. Executive Director, MSF, at the Global Health Council HHS Consultations, Washington D.C.